These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37553183)

  • 1. Functional tumor cell-intrinsic STING, not host STING, drives local and systemic antitumor immunity and therapy efficacy following cryoablation.
    Alshebremi M; Tomchuck SL; Myers JT; Kingsley DT; Eid S; Abiff M; Bonner M; Saab ST; Choi SH; Huang AY
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37553183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cryoablation triggers type I interferon-dependent antitumor immunity and potentiates immunotherapy efficacy in lung cancer.
    Gu C; Wang X; Wang K; Xie F; Chen L; Ji H; Sun J
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38272564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.
    Vonderhaar EP; Barnekow NS; McAllister D; McOlash L; Eid MA; Riese MJ; Tarakanova VL; Johnson BD; Dwinell MB
    Cell Mol Gastroenterol Hepatol; 2021; 12(1):41-58. PubMed ID: 33548597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity.
    Lemos H; Ou R; McCardle C; Lin Y; Calver J; Minett J; Chadli A; Huang L; Mellor AL
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32847988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 T cell-intrinsic STING signaling controls the differentiation and effector functions of T
    Benoit-Lizon I; Jacquin E; Rivera Vargas T; Richard C; Roussey A; Dal Zuffo L; Martin T; Melis A; Vinokurova D; Shahoei SH; Baeza Garcia A; Pignol C; Giorgiutti S; Carapito R; Boidot R; Végran F; Flavell RA; Ryffel B; Nelson ER; Soulas-Sprauel P; Lawrence T; Apetoh L
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35091453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STING Sensing of Murine Cytomegalovirus Alters the Tumor Microenvironment to Promote Antitumor Immunity.
    Wilski NA; Stotesbury C; Del Casale C; Montoya B; Wong E; Sigal LJ; Snyder CM
    J Immunol; 2020 Jun; 204(11):2961-2972. PubMed ID: 32284333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAK-676: A Novel Stimulator of Interferon Genes (STING) Agonist Promoting Durable IFN-dependent Antitumor Immunity in Preclinical Studies.
    Carideo Cunniff E; Sato Y; Mai D; Appleman VA; Iwasaki S; Kolev V; Matsuda A; Shi J; Mochizuki M; Yoshikawa M; Huang J; Shen L; Haridas S; Shinde V; Gemski C; Roberts ER; Ghasemi O; Bazzazi H; Menon S; Traore T; Shi P; Thelen TD; Conlon J; Abu-Yousif AO; Arendt C; Shaw MH; Okaniwa M
    Cancer Res Commun; 2022 Jun; 2(6):489-502. PubMed ID: 36923556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope spreading driven by the joint action of CART cells and pharmacological STING stimulation counteracts tumor escape via antigen-loss variants.
    Conde E; Vercher E; Soria-Castellano M; Suarez-Olmos J; Mancheño U; Elizalde E; Rodriguez ML; Glez-Vaz J; Casares N; Rodríguez-García E; Hommel M; González-Aseguinolaza G; Uranga-Murillo I; Pardo J; Alkorta G; Melero I; Lasarte J; Hervas-Stubbs S
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34810235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.
    Papaevangelou E; Esteves AM; Dasgupta P; Galustian C
    Front Immunol; 2023; 14():1196829. PubMed ID: 37465665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 monoclonal antibodies enhance the cryoablation-induced antitumor immune response: a breast cancer murine model research.
    Yu ZP; Sun XW; He YP; Gu J; Jin Y
    Int J Hyperthermia; 2023; 40(1):2164625. PubMed ID: 36966808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCG invokes superior STING-mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer.
    Lombardo KA; Obradovic A; Singh AK; Liu JL; Joice G; Kates M; Bishai W; McConkey D; Chaux A; Eich ML; Rezaei MK; Netto GJ; Drake CG; Tran P; Matoso A; Bivalacqua TJ
    J Pathol; 2022 Feb; 256(2):223-234. PubMed ID: 34731491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
    Jiang X; Wang J; Zheng X; Liu Z; Zhang X; Li Y; Wilhelm J; Cao J; Huang G; Zhang J; Sumer B; Lea J; Lu Z; Gao J; Luo M
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35623658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnitude of Therapeutic STING Activation Determines CD8
    Sivick KE; Desbien AL; Glickman LH; Reiner GL; Corrales L; Surh NH; Hudson TE; Vu UT; Francica BJ; Banda T; Katibah GE; Kanne DB; Leong JJ; Metchette K; Bruml JR; Ndubaku CO; McKenna JM; Feng Y; Zheng L; Bender SL; Cho CY; Leong ML; van Elsas A; Dubensky TW; McWhirter SM
    Cell Rep; 2018 Dec; 25(11):3074-3085.e5. PubMed ID: 30540940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
    Della Corte CM; Sen T; Gay CM; Ramkumar K; Diao L; Cardnell RJ; Rodriguez BL; Stewart CA; Papadimitrakopoulou VA; Gibson L; Fradette JJ; Wang Q; Fan Y; Peng DH; Negrao MV; Wistuba II; Fujimoto J; Solis Soto LM; Behrens C; Skoulidis F; Heymach JV; Wang J; Gibbons DL; Byers LA
    J Thorac Oncol; 2020 May; 15(5):777-791. PubMed ID: 32068166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of small-cell lung cancer associates with STING pathway activation and is enhanced by ATR and TOP1 inhibition.
    Li X; Li Y; Zhao Z; Miao N; Liu G; Deng L; Wei S; Hou J
    Cancer Med; 2023 Feb; 12(4):4864-4881. PubMed ID: 35957613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Hepatocellular Carcinoma by Multimodal In Situ Vaccination Using Cryoablation and a Plant Virus Immunostimulant.
    Ghani MA; Bangar A; Yang Y; Jung E; Sauceda C; Mandt T; Shukla S; Webster NJG; Steinmetz NF; Newton IG
    J Vasc Interv Radiol; 2023 Jul; 34(7):1247-1257.e8. PubMed ID: 36997021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Fluorouracil efficacy requires anti-tumor immunity triggered by cancer-cell-intrinsic STING.
    Tian J; Zhang D; Kurbatov V; Wang Q; Wang Y; Fang D; Wu L; Bosenberg M; Muzumdar MD; Khan S; Lu Q; Yan Q; Lu J
    EMBO J; 2021 Apr; 40(7):e106065. PubMed ID: 33615517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.
    Yi M; Niu M; Wu Y; Ge H; Jiao D; Zhu S; Zhang J; Yan Y; Zhou P; Chu Q; Wu K
    J Hematol Oncol; 2022 Oct; 15(1):142. PubMed ID: 36209176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.